Morimoto, Yoshihiro
Fushimi, Atsushi
Yamashita, Nami
Hagiwara, Masayuki
Bhattacharya, Atrayee
Cheng, Jingwei
Frost, Thomas C.
Ahmad, Rehan
Daimon, Tatsuaki
Huang, Lei
Hata, Tsuyoshi
Takahashi, Hidekazu
Yamamoto, Masaaki
Suzuki, Yozo http://orcid.org/0000-0002-4567-3802
DeCaprio, James A. http://orcid.org/0000-0002-0896-167X
Kufe, Donald http://orcid.org/0000-0001-5743-8888
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA97098, CA166480, CA233084)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | U.S. Public Health Service (R35CA232128, P01CA203655)
U.S. Department of Health & Human Services | U.S. Public Health Service
Article History
Received: 7 December 2021
Revised: 12 May 2022
Accepted: 23 May 2022
First Online: 10 June 2022
Competing interests
: DK has equity interests in Genus Oncology, Reata Pharmaceuticals, and Hillstream BioPharma and is a paid consultant to Reata and CanBas. The other authors declared no competing interests.